eligibility_summary
Adults ≥18 with classic FL (incl variants, not blastoid/FL3B), low tumor burden (mass<7 cm, ≤3 sites >3 cm, no B sx, compression, effusions), stage II-IV or stage I if not/can’t get RT, seek active care. Lesion ≥1.5 cm, imaging ≤49 d. No prior systemic therapy. Zubrod 0-2, adequate labs (LFTs, CrCl≥30). No uncontrolled infection, DM/HTN, heart disease, pregnant/nursing, PML, MAS/HLH, no autoimmunity/immunosuppression, HBV/HCV/HIV controlled, consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III trial in low–tumor-burden follicular lymphoma comparing rituximab vs mosunetuzumab. Drugs/mechanisms: - Rituximab: chimeric anti-CD20 monoclonal antibody (IgG1). Binds CD20 on B cells to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis, depleting CD20+ B cells. Given IV then SC, the SC co-formulation includes hyaluronidase human, an enzyme that facilitates subcutaneous absorption (not anticancer). - Mosunetuzumab (Lunsumio): subcutaneous CD20×CD3 bispecific monoclonal antibody (T‑cell–engaging). Simultaneously binds CD20 on malignant B cells and CD3 on T cells, activating T cells and redirecting cytotoxicity via immune synapse formation to kill B cells. Targets/pathways: CD20 on follicular lymphoma B cells, CD3 on T cells, effector pathways include ADCC/CDC (rituximab) and T‑cell–mediated cytotoxicity (mosunetuzumab).